This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ABX-1431

Abide Therapeutics Inc.

Drug Names(s): AB101131

Description: ABX-1431 is a first-in-class, orally active, selective, small molecule inhibitor of monoacylglycerol lipase (MGLL) which catalyzes the breakdown of the endogenous cannabinoid, 2-arachidonoylglycerol (2-AG), an endogenous ligand of the cannabinoid receptors CB1 and CB2, which are the molecular targets of the psychoactive component of Cannabis, delta-9 tetrahydrocannabinol (THC). MGLL is the major regulator of 2-AG levels available to signal through CB1 and CB2. CB1 is the primary cannabinoid receptor in the nervous system, and its activation accounts for most of the neurobehavioral effects of THC. CB2 is found primarily on immune cells and mediates the immunosuppressive effects of cannabinoids.

Deal Structure: Abide and Celgene
In February 2014, Abide Therapeutics announced it has entered into a strategic collaboration with Celgene Corporation to discover and develop new drugs in inflammation and immunology. Abide has pioneered innovative technologies to selectively target serine hydrolases, one of the largest enzyme families involved in regulating human physiology.

Under the terms of the agreement, Celgene paid to Abide an upfront payment. Celgene will take a small equity stake in Abide and will retain an exclusive option to acquire the company. Abide can earn additional payments if Celgene exercises its option to license the rest of the world rights on the first two products that reach the clinic. Furthermore, Abide may receive additional milestone payments upon successful development of those programs.

In September 2016, Abide Therapeutics announced that Celgene has exercised its option to obtain ex-US rights to Abides ABX-1431 for the potential treatment of...See full deal structure in Biomedtracker

Partners: Celgene Corporation


ABX-1431 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug